156 related articles for article (PubMed ID: 35253343)
1. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
Shimano KA; Eng W; Adams DM
Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29603. PubMed ID: 35253343
[TBL] [Abstract][Full Text] [Related]
2. A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies.
Al-Samkari H; Eng W
J Thromb Haemost; 2022 May; 20(5):1077-1088. PubMed ID: 35343049
[TBL] [Abstract][Full Text] [Related]
3. Vascular malformations syndromes: an update.
Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
[TBL] [Abstract][Full Text] [Related]
4. Syndromic vascular malformations related to the PIK3CA and RAS pathways: A clinical and imaging review.
Tsujioka Y; Nozaki T; Niimi Y; Starkey J; Hasegawa D; Kondo M; Enokizono M; Makidono A; Kono T; Jinzaki M
Clin Imaging; 2022 Sep; 89():162-173. PubMed ID: 35849880
[TBL] [Abstract][Full Text] [Related]
5. Genetic Basis and Therapies for Vascular Anomalies.
Queisser A; Seront E; Boon LM; Vikkula M
Circ Res; 2021 Jun; 129(1):155-173. PubMed ID: 34166070
[TBL] [Abstract][Full Text] [Related]
6. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.
Adams DM; Ricci KW
Hematol Oncol Clin North Am; 2019 Jun; 33(3):455-470. PubMed ID: 31030813
[TBL] [Abstract][Full Text] [Related]
7. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive phenotypic and genomic characterization of venous malformations.
Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
[TBL] [Abstract][Full Text] [Related]
9. Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications.
Pang C; Lim CS; Brookes J; Tsui J; Hamilton G
Vasc Med; 2020 Aug; 25(4):364-377. PubMed ID: 32568624
[TBL] [Abstract][Full Text] [Related]
10. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
[TBL] [Abstract][Full Text] [Related]
11. The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms.
Butnariu LI; Gorduza EV; Florea L; Țarcă E; Moisă ȘM; Trandafir LM; Stoleriu S; Bădescu MC; Luca AC; Popa S; Radu I; Cojocaru E
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293054
[TBL] [Abstract][Full Text] [Related]
12. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
13. Medical management of vascular anomalies of the head and neck.
Léauté-Labrèze C
J Oral Pathol Med; 2022 Nov; 51(10):837-843. PubMed ID: 35668029
[TBL] [Abstract][Full Text] [Related]
14. Congenital vascular lesions, could MAPK and PI3K inhibitors pave the way to new therapies?
Bisdorff-Bresson A; Eyries M; Boccara O
Curr Opin Oncol; 2021 Mar; 33(2):95-100. PubMed ID: 33481427
[TBL] [Abstract][Full Text] [Related]
15. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways and possible therapies for head and neck vascular anomalies.
Coulie J; Boon L; Vikkula M
J Oral Pathol Med; 2022 Nov; 51(10):878-887. PubMed ID: 35610188
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided Management.
Nicholson CL; Maguiness SM
Dermatol Clin; 2022 Apr; 40(2):127-136. PubMed ID: 35366967
[TBL] [Abstract][Full Text] [Related]
18. Medical management of vascular anomalies.
Trenor CC
Semin Cutan Med Surg; 2016 Sep; 35(3):177-81. PubMed ID: 27607327
[TBL] [Abstract][Full Text] [Related]
19. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
20. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
